Crohn's Disease Forum » Books, Multimedia, Research & News » New approach to preventing fibrosing strictures in IBD

01-15-2015, 06:34 PM   #1
Super Moderator
DustyKat's Avatar
Join Date: May 2010
Location: New South Wales, Australia
New approach to preventing fibrosing strictures in IBD

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

Crohn's disease—one form of inflammatory bowel disease (IBD)—is an incurable disorder that commonly presents in childhood and adolescence. Fibrosing strictures that can obstruct the intestines are a major complication of Crohn's disease. Although these obstructions can be removed surgically, disease tends to recur at those sites. As a result, patients are subjected to repeated surgeries over their lifetimes.

"We found that the antimicrobial defense protein cathelicidin can prevent such intestinal fibrosis in pre-clinical disease models," said senior study author Hon Wai Koon, PhD, from the David Geffen School of Medicine, University of California, Los Angeles. "These findings may lead to novel therapeutic approaches that prevent recurrent strictures in Crohn's disease patients."
Cathelicidin is part of a family of antimicrobial proteins produced by many cell types, including acute and chronic inflammatory and epithelial cells. Previous work has shown that cathelicidin also has anti-inflammatory properties and can suppress synthesis of collagen, the core protein of fibrotic scars, in skin.
In this study, researchers sought to determine whether cathelicidin is effective in preventing collagen synthesis and fibrosis in intestinal disease. Success in this area could spare Crohn's disease patients the strictures that often lead to bowel obstruction and multiple surgical resections that may leave so little bowel that nutrients cannot be adequately absorbed from food and nutrition and must be provided intravenously.

Investigators studied the effect of cathelicidin in two pre-clinical models of disease and human colonic fibroblasts, the cells that synthesize collagen in scars and strictures. One model of Crohn's disease that they used involved administration of the chemical trinitrobenzenesulfonic acid, which induces chronic colitis and fibrosis over seven weeks, to mice. Instilling cathelicidin protein through the colon over the last three weeks limited weight loss and microscopic features of disease while also reducing production of pro-inflammatory cytokines, e.g. tumor necrosis factor-α. Both microscopic evidence of fibrosis and production of mRNA for synthesis of collagen were also reduced. Interestingly, expression of transforming growth factor-α, which has anti-inflammatory and pro-regenerative activities, but is also implicated in fibrosis, was not affected by cathelicidin treatment.

"While the precise mechanisms by which cathelicidin promotes healing and inhibits fibrosis remain an area of future study, the advances described in this study may make it possible to prevent recurrent strictures and spare these patients from repeated surgery," said Jerrold Turner, MD, PhD, AGAF, editor-in-chief of Cellular and Molecular Gastroenterology and Hepatology.

Explore further: Crohn's study seeks to find causes of incurable bowel condition
More information: Jun Hwan Yoo, et al., Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis, Cellular and Molecular Gastroenterology and Hepatology 2015: 1(1): 55-74.e1,… (14)00002-2/abstract

Provided by American Gastroenterological Association
Mum of 2 kids with Crohn's.
01-15-2015, 08:17 PM   #2
Forum Monitor
DJW's Avatar
Join Date: Jul 2013
Location: Ontario

My Support Groups:
· Stoma
Crohn's Disease
DX 1978 (12 yrs old)
Ileostomy at 19

Visit Crohn's and Colitis Canada:

Living in Ontario with no drug benefits?

Trillium Drug Program:

01-15-2015, 09:02 PM   #3
Senior Member
rollinstone's Avatar
Join Date: Dec 2012

My Support Groups:
Good stuff!
-Are you looking for a new treatment option for your Crohn's disease? If so, I suggest you look into the ongoing clinical trial by Qu Biologics for their SSI treatment. Click here for more information or to help spread the word.
01-19-2015, 09:51 PM   #4
Senior Member
xeridea's Avatar
Join Date: Jul 2014

My Support Groups:
Gosh, why do things keep harking back to vitamin D with this disease? Cathlicidin, the agent identified in the study DustyKat mentions, is part of the Vit. D system.

... identification of the cationic antimicrobial peptide cathelicidin as a vitamin D target gene (Gombart et al., 2005) and of CYP27B1 and VDR upregulation in monocytes as the link between Toll-like receptor-2 (TLR-2) activation on the one hand and cathelicidin production and intracellular mycobacteria killing on the other hand (Liu et al., 2006) created a previously unknown and unexpected link between innate immunity and the vitamin D system.

This same pathways are implicated in the TLR response in the innate immunity system. More specifically

...Activation of TLRs results in a direct antimicrobial response in monocytes and macrophages...we observed that activation of TLR2/1 reduced the viability of intracellular M. tuberculosis in human monocytes and macrophages

I wish I could put together some of these pieces together better. I just lack the background. Darn it!

Crohn's Disease Forum » Books, Multimedia, Research & News » New approach to preventing fibrosing strictures in IBD
Thread Tools

All times are GMT -5. The time now is 03:40 AM.
Copyright 2006-2017